"TRB Chemedica is pleased to be associated with Alcon and Lantibio, through the signature of this licensing agreement, to bringing to the USA Dry Eye Syndrome patients our high-value eye drop therapy based on a unique hyaluronic acid and essential ions patented formulation," said Dr. Guido DiNapoli, founder and owner of TRB Chemedica. "TRB Chemedica is looking forward to working in close collaboration with Alcon and Lantibio."
The most common causes of Dry Eye Syndrome are ocular surgery, environmental factors such as dust and pollutants, and hormonal changes associated with menopause. Symptoms of dry eye syndrome include burning, itching, irritation, photophobia, and a feeling that there is a foreign body in the eye. If left untreated, it can cause permanent damage, including impaired vision. In 2003, Morgan Stanley Research estimated the prevalence of dry eye syndrome in the United States at 5.5 million diagnosed cases.
In a related affliction, Sjogren's syndrome patients suffer dry eyes and dry mouth. Sjogren's syndrome is one of the most prevalent autoimmune disorders, striking as many as 3 million Americans. More than 90 percent of Sjogren's syndrome sufferers are women and while prevalence increases with age, the average age of onset is in the late 40's.
About Lantibio & Paramount BioSciences
Lantibio, Inc. is a private pharmaceutical company funded by Paramount
BioSciences and devoted to the discovery, development, and
commercialization of products for the treatment of ocular disease and
serious respiratory diseases. For more information on Lantibio, Inc., visit
the Company's web site at http://www.lantibio.com. Paramount BioSciences,
LLC is a global pharmaceutical development and healthcare investment firm
that conceives, nurtures, and supports new biote
|SOURCE Lantibio, Inc.|
Copyright©2007 PR Newswire.
All rights reserved